Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8340776 | 0.84 | L3MBTL1 (0.56) | SLC6A2SLC6A4L3MBTL1HRH3HPGD | |
| SCHEMBL853431 | 0.84 | MAPT (0.53) | SLC6A2SLC6A4L3MBTL1HPGDALDH1A1 | |
| SCHEMBL15765651 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A4L3MBTL1HRH3HPGD | |
| SCHEMBL157609 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A4L3MBTL1ALDH1A1CTSG | |
| SCHEMBL12499505 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A4L3MBTL1HPGDALDH1A1 | |
| SCHEMBL156594 | 0.81 | NPC1 (0.55) | SLC6A2SLC6A4L3MBTL1HPGDALDH1A1 | |
| SCHEMBL17538303 | 0.79 | ALDH1A1 (0.57) | SLC6A2SLC6A4L3MBTL1HPGDALDH1A1 | |
| SCHEMBL15672568 | 0.79 | L3MBTL1 (0.50) | SLC6A2SLC6A4L3MBTL1HPGDALDH1A1 | |
| SCHEMBL14570546 | 0.79 | POLB (0.50) | SLC6A2SLC6A4L3MBTL1CTSGCMA1 | |
| SCHEMBL22121727 | 0.79 | SLC6A2 (0.45) | SLC6A2SLC6A4L3MBTL1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745311-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745311-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745311-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9388185-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388185-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388185-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014026125-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2013051672-A1 | MEDICINAL AGENT COMPRISING THIAZOLIDINE DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | 株式会社ヤクルト本社 (JP) | 2013-04-11 | — | — | WO | disclosed |
| WO-2012048411-A1 | PLK-4 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR2, FGFR3 | SLC6A2 4844/4885SLC6A4 4760/4885L3MBTL1 4167/4885 |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR2, FGFR3 | SLC6A2 4844/4885SLC6A4 4760/4885L3MBTL1 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.